Phase III ADVANCE: 96-Wk Primary Efficacy Analysis of DTG + FTC/(TAF or TDF) vs EFV/FTC/TDF in ART-Naive PWH in South Africa

July 6-10, 2020; Virtual
Noninferiority of first-line DTG-based vs EFV-based regimens maintained through Week 96, with significantly greater weight gain observed in PWH receiving DTG + FTC/TAF.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 10, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

CCO commentary by Dr. Darcy Wooten on data presented at CROI 2021 regarding integrase strand inhibitor-associated weight gain and clinical implications

Darcy Wooten, MD Released: May 5, 2021

Download free expert-authored slides to see how clinicians use HIV-ASSIST to choose appropriate, guideline-based antiretroviral therapy

Jehan Budak, MD Ethel D. Weld, MD, PhD Released: April 26, 2021

Free expert slides from Clinical Care Options (CCO) reviewing the use of HIV-ASSIST for ART and LTBI treatment selection in a patient with HIV

Nicky Mehtani, MD, MPH Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.